

February 13, 2017

# Relmada Therapeutics to Participate in BIO CEO and Investor Conference

## Company Presentation on February 14, 2017 at 10:30am ET

NEW YORK, Feb. 13, 2017 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that the company will participate in the BIO CEO and Investor Conference to be held February 13-14, 2017 at the Waldorf Astoria in New York City.



Sergio Traversa, chief executive officer of Relmada, is scheduled to present on Tuesday, February 14th at 10:30am ET in the Conrad presentation room.

The BIO CEO and Investor Conference is focused on established and emerging publicly traded and select private biotech companies. For more information, visit <https://www.bio.org/events/bio-ceo-investor-conference>.

A live webcast of the presentation will be available through the Company's website at [www.relmada.com](http://www.relmada.com). Please register at least 10 minutes prior to the start of the presentation to ensure timely access. The webcast and presentation will also be archived on the website for 90 days after the conference.

## **About Relmada Therapeutics, Inc.**

Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. The Company has a diversified portfolio of four products at various stages of development, including d-Methadone (dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist for depression and neuropathic pain; LevoCap ER (REL-1015), an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; oral buprenorphine (BuTab, REL-1028), an oral dosage form of the opioid analgesic buprenorphine; and topical mepivacaine (MepiGel, REL-1021), an orphan drug designated topical formulation of the local anesthetic mepivacaine. The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team. The Company's approach is expected to reduce clinical development risks and costs while potentially delivering valuable products to address areas of high unmet medical needs. For more information, please visit Relmada's website at: [www.relmada.com](http://www.relmada.com).

## **Forward-Looking Statements**

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. We may from time to time make written or oral statements in this letter, the proxy statements filed with the SEC communications to stockholders and press releases which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based upon management's current expectations, estimates, assumptions and beliefs concerning future events and conditions and may discuss, among other things, anticipated future performance, expected product development, product potential, future business plans and costs. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to" and similar expressions. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all of the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be considered to be a complete list.

## **Contact**

Investor Contact:

Michael Becker, Chief Financial Officer

Relmada Therapeutics Inc.

Tel: 646-677-3857

[mbecker@relmada.com](mailto:mbecker@relmada.com)

Media Contact:

Lynn Granito

Berry & Company Public Relations

Tel: 212-253-8881  
[lgranito@berrypr.com](mailto:lgranito@berrypr.com)



To view the original version on PR Newswire, visit <http://www.prnewswire.com/news-releases/relmada-therapeutics-to-participate-in-bio-ceo-and-investor-conference-300406088.html>

SOURCE Relmada Therapeutics, Inc.